GB9908175D0 - Method of treating neurological disorders - Google Patents

Method of treating neurological disorders

Info

Publication number
GB9908175D0
GB9908175D0 GBGB9908175.4A GB9908175A GB9908175D0 GB 9908175 D0 GB9908175 D0 GB 9908175D0 GB 9908175 A GB9908175 A GB 9908175A GB 9908175 D0 GB9908175 D0 GB 9908175D0
Authority
GB
United Kingdom
Prior art keywords
neurological disorders
treating neurological
treating
disorders
neurological
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9908175.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to GBGB9908175.4A priority Critical patent/GB9908175D0/en
Publication of GB9908175D0 publication Critical patent/GB9908175D0/en
Priority to PCT/GB2000/001284 priority patent/WO2000061126A2/en
Priority to AU39777/00A priority patent/AU3977700A/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
GBGB9908175.4A 1999-04-09 1999-04-09 Method of treating neurological disorders Ceased GB9908175D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB9908175.4A GB9908175D0 (en) 1999-04-09 1999-04-09 Method of treating neurological disorders
PCT/GB2000/001284 WO2000061126A2 (en) 1999-04-09 2000-04-06 Method of treating neurological disorders with combinations of nitric oxide synthase inhibitors and excitatory amino acid receptor modulators
AU39777/00A AU3977700A (en) 1999-04-09 2000-04-06 Method of treating neurological disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9908175.4A GB9908175D0 (en) 1999-04-09 1999-04-09 Method of treating neurological disorders

Publications (1)

Publication Number Publication Date
GB9908175D0 true GB9908175D0 (en) 1999-06-02

Family

ID=10851263

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9908175.4A Ceased GB9908175D0 (en) 1999-04-09 1999-04-09 Method of treating neurological disorders

Country Status (3)

Country Link
AU (1) AU3977700A (en)
GB (1) GB9908175D0 (en)
WO (1) WO2000061126A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK8242003A3 (en) * 2001-01-05 2004-01-08 Lilly Co Eli Excitatory amino acid receptor antagonists
US20040138204A1 (en) * 2002-10-30 2004-07-15 Harrington James Frederick Compositions and methods for pain reduction
TWI417095B (en) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mglur2-receptors
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TWI445532B (en) 2007-09-14 2014-07-21 Janssen Pharmaceuticals Inc 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-[1,4'] bipyridinyl-2'-ones
CA2735764C (en) 2008-09-02 2016-06-14 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
WO2010060589A1 (en) 2008-11-28 2010-06-03 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
SG176018A1 (en) 2009-05-12 2011-12-29 Janssen Pharmaceuticals Inc 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MX2011011964A (en) 2009-05-12 2012-02-23 Janssen Pharmaceuticals Inc 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders.
EP2338492A1 (en) * 2009-12-24 2011-06-29 Universidad del Pais Vasco Methods and compositions for the treatment of alzheimer
JP5852666B2 (en) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド 1,2,4-Triazolo [4,3-a] pyridine derivatives and their use as positive allosteric modulators of the mGluR2 receptor
ES2536433T3 (en) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. 1,2,4-Triazolo [4,3-a] pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
PL2649069T3 (en) 2010-11-08 2016-01-29 Janssen Pharmaceuticals Inc 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
JO3368B1 (en) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
JO3367B1 (en) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
DK3096790T3 (en) 2014-01-21 2019-10-07 Janssen Pharmaceutica Nv COMBINATIONS INCLUDING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROP GLUTAMATERG SUBTYPE 2 RECEPTOR AND APPLICATION OF THESE
UA127921C2 (en) 2014-01-21 2024-02-14 Янссен Фармацевтика Нв Combinations containing positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455279A (en) * 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
US5225440A (en) * 1991-09-13 1993-07-06 The United States Of America As Represented By The Department Of Health And Human Services Attenuation of the opioid withdrawal syndrome by inhibitors of nitric oxide synthase
FR2707645B1 (en) * 1993-07-16 1995-08-11 Rhone Poulenc Rorer Sa Imidazo [1,2-a] pirazine-4-one derivatives, their preparation and drugs containing them.
WO1996021445A1 (en) * 1995-01-13 1996-07-18 The General Hospital Corporation Methods of inhibiting neurodegenerative diseases
US5614508A (en) * 1995-06-07 1997-03-25 Warner-Lambert Company Amino acid derivatives of substituted quinoxaline 2,3-dione derivatives as glutamate receptor antagonists
US5747532A (en) * 1995-11-21 1998-05-05 Medinox, Inc. Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor
CA2238029A1 (en) * 1996-03-05 1997-09-12 Medinox, Inc. Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor
CN1244864A (en) * 1996-11-25 2000-02-16 普罗克特和甘保尔公司 2-imidazolinylaminoindazole compounds useful as alpha-2 adrenoceptor agonists
ATE279919T1 (en) * 1997-08-15 2004-11-15 Carolyn Ann Fairbanks AGMATINE FOR THE TREATMENT OF NEUROPATHIC PAIN
US6103872A (en) * 1998-01-22 2000-08-15 The Johns Hopkins University CAPON: a protein associated with neuronal nitric oxide synthase

Also Published As

Publication number Publication date
AU3977700A (en) 2000-11-14
WO2000061126A3 (en) 2001-08-23
WO2000061126A2 (en) 2000-10-19

Similar Documents

Publication Publication Date Title
HUP0200495A2 (en) Method of treating eating disorders
IL141263A0 (en) Methods for treatment of neurological disorders
GB9908175D0 (en) Method of treating neurological disorders
GB2351661B (en) Novel method of treatment
IL144172A0 (en) Method of treating sexual disturbances
IL134289A0 (en) Methods for treating neurological deficits
AU4868599A (en) Composition for and method of treating neurological disorders
IL145875A0 (en) Novel method of treatment
EP1207874A4 (en) Methods of treating proliferative disorders
EP1239851A4 (en) Treatment of hyperproliferative disorders
GB9926968D0 (en) Treatment of neurological disorders
AU4552200A (en) Method of treating psychotic disorders
AU3757300A (en) Method of treating anxiety disorders
HUP0102886A2 (en) Treatment of anxiety disorders
GB9930688D0 (en) Novel method of treatment
IL139943A0 (en) Method of treatment
EP1135128A4 (en) Novel method of treatment
EP1094863A4 (en) Methods for treating neurological injuries and disorders
GB9930696D0 (en) Novel method of treatment
GB9822681D0 (en) Method of treatment
AU2002237894A1 (en) Methods of treating neurological disorders
EG24158A (en) Novel method of treatment
TJ99000556A (en) Method of treatment of nevrodermite
GB9915597D0 (en) Method of treatment
GB9903950D0 (en) Method of treatment

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)